Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

Trial Details

NCT ID
NCT07249346
Phase
PHASE2
Sponsor
Hannah Choe, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ruxolitinib
  • Myeloablative conditioning regimen
  • Hematopoietic Stem Cell Transplantation
  • Cyclophosphamide
  • Tacrolimus
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Age 18.0 years or older at the time of enrollment
  • Patients undergoing allogeneic hematopoietic cell transplantation for one of the following indications:
  • Acute leukemia with no circulating blasts and with less than 5% blasts in the bone marrow
  • Myelodysplasia/chronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →